Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes

Blood

Volumn 96, Issue 2, 2000, Pages 647-654

  Zambello, Renato ^b   Trentin, Livio ^b   Facco, Monica ^b   Siviero, Marta ^b   Galvan, Silvia ^b   Piazza, Francesco ^b   Perin, Alessandra ^b   Agostini, Carlo ^b   Semenzato, Gianpietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD40 ANTIGEN; CD56 ANTIGEN; CD70 ANTIGEN; FAS ANTIGEN; GLYCOPROTEIN GP 39; LIGAND; LIPOCORTIN 5; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LARGE GRANULAR LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034661924     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.2.647.014k18_647_654     Document Type: Article

References (42)

1. Loughran TPJ. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1-14.
2. Oshimi K, Yamada O. Kaneko J, et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia. 1993;7:782-788.
3. Pandolfi F, Zambello R, Cafaro A, Semenzato G. Biological and clinical heterogeneity of lymphoproliferative diseases of peripheral mature T-lymphocytes. Lab Invest. 1992;67:224-235.
4. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TPJ. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;86:256-260.
5. Zambello R, Trentin L, Bulian P, et al. Role of tumor necrosis factor-α and its specific 55-kd and 75-kd receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1992;80:2030-2037.
6. Armitage RJ. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol. 1994;6:407-414.
7. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996; 334:1717-1725.
8. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell. 1994; 75:959-962.
9. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to tumor necrosis factor. Cell. 1993;73:1349-1358.
10. Gruss HJ, Boiani N, Williams DE, Armitage RJ, Smith CA, Goodwin RG. Pleiotropic effects of CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83:2045-2051.
11. Nakajima A, Kodama T, Morimoto S, et al. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J Immunol. 1998;161:1901-1907.
12. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. CD40 and CD70 co-stimulate a potent in vivo antitumor T cell response. J Immunother. 1998;21:225-236.
13. Courdec B, Zitvogel L, Douin-Echinard V, et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) and CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998;5:163-175.
14. Borrow T, Tishon A, Lee S, et al. CD40L-deficient mice show deficits in antiviral immunity and have impaired memory CD8 CTL response. J Exp Med. 1996;183:2129-2142.
15. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
16. Shoenberger SP, Toes RE, van der Voort El, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40/CD40L interactions. Nature. 1998;393:480-483.
17. Carbone A, Ruggiero G, Terrazzano G, et al. A new mechanism of NK cell cytotoxicity activation: the CD40-CD40L ligand interaction. J Exp Med. 1997;185:2053-60.
18. Linch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune response. Immunol Today. 1995;16:569-574.
19. Alderson MR, Armitage RJ, Maraskovsky E, et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 1993;178:2231-2235.
20. Zambello R, Facco M, Trentin L, et al. Interleukin-15 triggers the proliferation and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood. 1997;89:200-211.
21. Orengo AM, Cantoni C, Neglia F, Biassoni R, Ferrini S. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Clin Exp Immunol. 1997;107:608-613.
22. Vermas I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apopotosis on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184:39-51.
23. Zipp F, Martin R, Lichtenfels R, et al. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J Immunol. 1997;159:2108-2112.
24. + granular lymphocytes. Cancer Res. 1995;55:6140-6148.
25. Trentin L, Zambello R, Sancetta R, et al. B lymphocytes from patients with lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Res. 1997;57:4940-4947.
26. Gruss HJ, Dower SK. Tumor necrosis factor ligand superfamily: involvement of the pathology of malignant lymphomas. Blood. 1995;85:3378-3404.
27. + T cells isolated from peripheral blood lymphocytes on normal donors. J Immunol. 1996;157:3229-3234.
28. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med. 1995;181:1235-1238.
29. Armant M, Armitage R, Boiani N, Delespesse G, Sarfati M. Functional CD40L expression in the absence of T cell receptor engagement: involvement in interleukin-2-induced, interleukin-12 and interferon-γ. Eur J Immunol.1996;26:1430-1434.
30. Inghirami G, Lederman S, Yellin MJ, Chadburn A, Chess L, Knowles DM. Phenotypic and functional characterization of T-BAM (CD40 ligand) T-cell non-Hodgkin's lymphoma. Blood. 1994;84:866-873.
31. Knapp W, Dorken B, Rieber EP, et al. Leukocyte Typing IV: White Cell Differentiation Antigens. Oxford, UK: Oxford University Press; 1989.
32. TanaKa M, SudaT, Haze K, et al. Fas ligand in human serum. Nature Med. 1996;2:317-322.
33. Persova R, Loughran TP Jr. Constitutive expression of Fas ligand in large granular lymphocyte leukemia. Br J Haematol. 1997;97:123-129.
34. Hintzen RQ, De Jong R. Lens SMA, van Lier RAW. CD27: marker and mediator of T cell activation? Immunol Today. 1994;15:307-311.
35. Oshimi K, Shinkai Y, Okumura K, Oshimi Y, Mizoguchi H. Perforin gene expression in granular lymphocyte proliterative disorders. Blood. 1990;75:704-711.
36. Kasten-Sportes C, Zacnoen S, Steis RG, Chan WC, Winton EF, Waldman TA. T cell receptor gene rearrangement in T-cell large granular leukocyte leukemia: preferential Vα but diverse Jα usage in one of five patients. Blood. 1994;83:767-775.
37. Zambello R, Semenzato G. Large granular lymphocytosis. Haematologica. 1998;83:936-942.
38. Zambello R, Trentin L, Ciccone E, et al. Phenotypic diversity of natural killer populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood. 1993;81:2381-2385.
39. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP Jr. Disregulation of CD95/CD95 ligand-apoptotic pathway in CD3+ large granular lymphocyte leukemia. Blood. 1998;92:4771-4777.
40. Moretta A, Biassoni R, Bottino C, et al. Major histocompatibility complex class-I specific receptors on human natural killer and T lymphocytes. Immunol Rev. 1997;155:105-116.
41. Sivori S, Pende D, Bottino C, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh and cultured human natural killer cells: correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999;29:1656-1666.
42. Hangretinger R, Geiselhart A, Moris A, et al. Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-inhibitory receptors. N Engl J Med. 1999;340:278-284.